Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion
- PMID: 26826180
- DOI: 10.1161/CIRCULATIONAHA.115.012427
Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion
Abstract
Background: Fingolimod, a sphingosine-1-phosphate receptor agonist, is used for the treatment of multiple sclerosis and exerts antiapoptotic properties. We hypothesized that sphingosine-1-phosphate receptor activation with fingolimod during acute myocardial infarction (MI) inhibits apoptosis, leading to increased myocardial salvage, reduced infarct size, and mitigated left ventricular (LV) remodeling in a porcine model of ischemia/reperfusion.
Methods and results: Ischemia/reperfusion was induced in pigs by balloon occlusion of the left anterior descending artery, followed by reperfusion. Animals randomly received fingolimod or saline (control). In short-term experiments, fingolimod treatment activated the cardioprotective reperfusion injury salvage kinase and survivor activating factor enhancement pathways in the infarct border zone 24 hours after MI, leading to decreased cardiomyocyte apoptosis and reduced myocardial oxidative stress. These effects were abolished by specific inhibitors of both pathways, demonstrating that fingolimod-induced cardioprotection was mediated by reperfusion injury salvage kinase and survivor activating factor enhancement pathways. In long-term experiments, fingolimod significantly improved myocardial salvage, reduced infarct size, and improved systolic LV function measured by cardiac magnetic resonance 1 week and 1 month after MI. Importantly, fingolimod mitigated the development of adverse post-MI LV remodeling 1 month after MI. Specifically, fingolimod treatment led to a significant reduction in LV mass, LV dilatation, and neurohormonal activation, and it preserved LV geometry. Furthermore, fingolimod decreased interstitial fibrosis, cardiomyocyte hypertrophy, and chronic activation of Akt and extracellular receptor kinase 1/2 in the remote noninfarcted myocardium.
Conclusions: Sphingosine-1-phosphate receptor activation with fingolimod during acute MI reduced infarct size via the reperfusion injury salvage kinase and survivor activating factor enhancement pathways, improved systolic LV function, and mitigated post-MI LV remodeling. Our data strongly support a cardioprotective role for sphingosine-1-phosphate receptor activation during MI.
Keywords: apoptosis; cardiovascular diseases; ischemia; models, animal; myocardial infarction; reperfusion injury; ventricular remodeling.
© 2016 American Heart Association, Inc.
Similar articles
-
TVP1022: A Novel Cardioprotective Drug Attenuates Left Ventricular Remodeling After Ischemia/Reperfusion in Pigs.J Cardiovasc Pharmacol. 2015 Aug;66(2):214-22. doi: 10.1097/FJC.0000000000000267. J Cardiovasc Pharmacol. 2015. PMID: 25900266
-
Durable Benefits of Cellular Postconditioning: Long-Term Effects of Allogeneic Cardiosphere-Derived Cells Infused After Reperfusion in Pigs with Acute Myocardial Infarction.J Am Heart Assoc. 2016 Feb 8;5(2):e002796. doi: 10.1161/JAHA.115.002796. J Am Heart Assoc. 2016. PMID: 26857066 Free PMC article.
-
The role of cytoprotective cytokines in cardiac ischemia/reperfusion injury.J Surg Res. 2008 Aug;148(2):164-71. doi: 10.1016/j.jss.2007.08.005. Epub 2007 Aug 31. J Surg Res. 2008. PMID: 18067924
-
Update on the Protective Role of Regulatory T Cells in Myocardial Infarction: A Promising Therapy to Repair the Heart.J Cardiovasc Pharmacol. 2016 Dec;68(6):401-413. doi: 10.1097/FJC.0000000000000436. J Cardiovasc Pharmacol. 2016. PMID: 27941502 Review.
-
The role of aldosterone inhibitors in cardiac ischemia-reperfusion injury.Can J Physiol Pharmacol. 2021 Jan;99(1):18-29. doi: 10.1139/cjpp-2020-0276. Epub 2020 Aug 15. Can J Physiol Pharmacol. 2021. PMID: 32799671 Review.
Cited by
-
The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction.Cells. 2020 Sep 21;9(9):2134. doi: 10.3390/cells9092134. Cells. 2020. PMID: 32967374 Free PMC article. Review.
-
Sphingosine 1-phosphate: Lipid signaling in pathology and therapy.Science. 2019 Oct 18;366(6463):eaar5551. doi: 10.1126/science.aar5551. Science. 2019. PMID: 31624181 Free PMC article. Review.
-
High-density lipoproteins during sepsis: from bench to bedside.Crit Care. 2020 Apr 7;24(1):134. doi: 10.1186/s13054-020-02860-3. Crit Care. 2020. PMID: 32264946 Free PMC article. Review.
-
Fingolimod Plays Role in Attenuation of Myocardial Injury Related to Experimental Model of Cardiac Arrest and Extracorporeal Life Support Resuscitation.Int J Mol Sci. 2019 Dec 11;20(24):6237. doi: 10.3390/ijms20246237. Int J Mol Sci. 2019. PMID: 31835656 Free PMC article.
-
S1P Lyase Inhibition Starting After Ischemia/Reperfusion Improves Postischemic Cardiac Remodeling.JACC Basic Transl Sci. 2022 May 23;7(5):498-499. doi: 10.1016/j.jacbts.2022.03.009. eCollection 2022 May. JACC Basic Transl Sci. 2022. PMID: 35663625 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical